25 Ces Urol 2022; 26(1): 13–28 PŘEHLEDOVÉ ČLÁNKY 51. You D, Jeong IG, Song C, et al. Analysis of pre‑operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted the‑ rapy era. Jpn J Clin Oncol. 2015; 45(1): 96–102. doi:10.1093/jjco/hyu171. 52. Fukuda H, Takagi T, Kondo T, et al. Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy. Int J Clin Oncol. 2018; 23(3): 539–546. doi:10.1007/s10147-017-1221-z. 53. Marchioni M, Kriegmair M, Heck M, et al. Development of a Novel Risk Score to Select the Optimal Can‑ didate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi‑institutional Registry (REMARCC). Eur Urol Oncol. 2021; 4(2): 256–263. doi:10.1016/j.euo.2020. 12. 010. 54. Kutikov A, Uzzo RG, Caraway A, et al. Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU Int. 2009; 106(2): 218–223. doi:10.1111/j.1464-410X.2009.09079.x. 55. Culp SH, Tannir NM, Abel EJ, et al. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer. 2010; 116(14): 3378–3388. doi:10.1002/cncr.25046. 56. Bamias A, Tzannis K, Papatsoris A, et al. Prognostic Significance of Cytoreductive Nephrectomy in Patients With Synchronous Metastases From Renal Cell Carcinoma Treated With First‑Line Sunitinib: A Eu‑ ropean Multiinstitutional Study. Clin Genitourin Cancer. 2014; 12(5): 373–383. doi:10.1016/j.clgc.2014. 03. 012. 57. Zhao Z, Wu W, Duan X, Zeng G, Liu Y. The value of cytoreductive nephrectomy on the survival of metastatic renal carcinoma patients based on the number of site‑specific metastases. Kimple RJ, ed. PLoS One. 2019; 14(4): e0215861. doi:10.1371/journal.pone.0215861. 58. Choueiri TK, Xie W, Kollmannsberger C, et al. The Impact of Cytoreductive Nephrectomy on Survival of Patients With Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Targeted Therapy. J Urol. 2011; 185(1): 60–66. doi:10.1016/j.juro.2010. 09. 012. 59. Conti SL, Thomas I‑C, Hagedorn JC, et al. Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. Int J Cancer. 2014; 134(9): 2245–2252. doi:10.1002/ijc.28553. 60. Abern MR, Scosyrev E, Tsivian M, et al. Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted‑therapy era. Anticancer Res. 2014; 34(5): 2405–2411. http:// www.ncbi.nlm.nih.gov/pubmed/24778051. 61. Hanna N, Sun M, Meyer CP, et al. Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study. J Clin Oncol. 2016; 34(27): 3267–3275. doi:10.1200/JCO.2016. 66. 7931. 62. Mathieu R, Pignot G, Ingles A, et al. Nephrectomy improves overall survival in patients with metasta‑ tic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features. Urol Oncol Semin Orig Investig. 2015; 33(8): 339.e9–339.e15. doi:10.1016/j.urolonc.2015. 05. 014. 63. de Groot S, Redekop WK, Sleijfer S, et al. Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population‑based Registry. Urology. 2016; 95: 121–127. doi:10.1016/j.urology.2016. 04. 042. 64. Palumbo C, Mistretta FA, Knipper S, et al. Contemporary Cytoreductive Nephrectomy Provides Sur‑ vival Benefit in Clear‑cell Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2020; 18(6): e730–e738. doi:10.1016/j.clgc.2020. 05. 009. 65. Warren M, Venner PM, North S, et al. A population‑based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment. Can Urol Assoc J. 2013; 3(4): 281. doi:10.5489/cuaj.1121. 66. Kroeger N, Xie W, Lee J‑L, et al. Metastatic non‑clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer. 2013; 119(16): 2999–3006. doi:10.1002/cncr.28151.
RkJQdWJsaXNoZXIy NDA4Mjc=